Next Article in Journal
Traceability of “Tuscan PGI” Extra Virgin Olive Oils by 1H NMR Metabolic Profiles Collection and Analysis
Previous Article in Journal
Identifying Antibacterial Compounds in Black Walnuts (Juglans nigra) Using a Metabolomics Approach
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessArticle
Metabolites 2018, 8(4), 59;

A Framework for Development of Useful Metabolomic Biomarkers and Their Effective Knowledge Translation

Faculty of Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada
Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB T2N 1N4, Canada
Department of Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada
Author to whom correspondence should be addressed.
Received: 6 September 2018 / Revised: 27 September 2018 / Accepted: 28 September 2018 / Published: 30 September 2018
Full-Text   |   PDF [855 KB, uploaded 30 September 2018]   |  


Despite the significant advantages of metabolomic biomarkers, no diagnostic tests based on metabolomics have been introduced to clinical use. There are many reasons for this, centered around substantial obstacles in developing clinically useful metabolomic biomarkers. Most significant is the need for interdisciplinary teams with expertise in metabolomics, analysis of complex clinical and metabolomic data, and clinical care. Importantly, the clinical need must precede biomarker discovery, and the experimental design for discovery and validation must reflect the purpose of the biomarker. Standard operating procedures for procuring and handling samples must be developed from the beginning, to ensure experimental integrity. Assay design is another challenge, as there is not much precedent informing this. Another obstacle is that it is not yet clear how to protect any intellectual property related to metabolomic biomarkers. Viewing a metabolomic biomarker as a natural phenomenon would inhibit patent protection and potentially stifle commercial interest. However, demonstrating that a metabolomic biomarker is actually a derivative of a natural phenomenon that requires innovation would enhance investment in this field. Finally, effective knowledge translation strategies must be implemented, which will require engagement with end users (clinicians and lab physicians), patient advocate groups, policy makers, and payer organizations. Addressing each of these issues comprises the framework for introducing a metabolomic biomarker to practice. View Full-Text
Keywords: metabolomics; biomarkers; knowledge translation metabolomics; biomarkers; knowledge translation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Marchand, C.R.; Farshidfar, F.; Rattner, J.; Bathe, O.F. A Framework for Development of Useful Metabolomic Biomarkers and Their Effective Knowledge Translation. Metabolites 2018, 8, 59.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top